A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

BACKGROUND: The effective treatment of triple-negative breast cancer (TNBC) remains a profound clinical challenge. Despite frequent epidermal growth factor receptor (EGFR) overexpression and reliance on downstream signalling pathways in TNBC, resistance to EGFR-tyrosine kinase inhibitors (TKIs) rema...

Descripción completa

Detalles Bibliográficos
Autores principales: McLaughlin, Ronan P., He, Jichao, van der Noord, Vera E., Redel, Jevin, Foekens, John A., Martens, John W. M., Smid, Marcel, Zhang, Yinghui, van de Water, Bob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604188/
https://www.ncbi.nlm.nih.gov/pubmed/31262335
http://dx.doi.org/10.1186/s13058-019-1161-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604188/
https://www.ncbi.nlm.nih.gov/pubmed/31262335
http://dx.doi.org/10.1186/s13058-019-1161-9

Ejemplares similares